Возможности блокатора рецепторов к ангиотензину азилсартана медоксомила и его комбинации с хлорталидоном в снижении сердечно-сосудистого риска у пациентов с ожирением, метаболическим синдромом и сахарным диабетом

Для лечения артериальной гипертонии все чаще применяются блокаторы рецепторов к ангиотензину (БРА), особенно актуален этот класс препаратов у пациентов с ожирением, метаболическим синдромом и сахарным диабетом. Однако не все БРА могут стать препаратами первого выбора у этой категории пациентов. К антигипертензивным препаратам для больных артериальной гипертонией с метаболическими нарушениями предъявляются особые требования - высокая антигипертензивная эффективность, максимальная продолжительность действия, возможность улучшать чувствительность периферических тканей к инсулину и, соответственно, метаболический профиль. Кроме того, данная категория пациентов нуждается в комбинированной терапии уже на старте лечения. Комбинаций БРА, обладающих всеми этими свойствами, с тиазидоподобными диуретиками крайне мало. Настоящий обзор посвящен возможностям нового БРА азилсартана медоксомила (Эдарби®) и его комбинации с хлорталидоном (Эдарби® Кло) в снижении сердечно-сосудистого риска у пациентов с ожирением, метаболическим синдромом и сахарным диабетом.

артериальная гипертония, ожирение, метаболический синдром, сахарный диабет, блокаторы рецепторов к ангиотензину, хлорталидон, антигипертензивная терапия, комбинированная терапия, сердечно-сосудистый риск

1. Emdin C.A, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015; 313: 603-15.

2. Ettehad D, Emdin C.A, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-67.

3. Forouzanfar M.H, Liu P, Roth G.A et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317: 165-82.

4. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.

5. NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet 2017; 389: 37-55.

6. O’Donnell M.J, Chin S.L, Rangarajan S et al. INTERSTROKE Investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet 2016; 388: 761-75.

7. Rapsomaniki E, Timmis A, George J et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014; 383: 1899-911.

8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014; 32: 2285-95.

9. Tsai W.C, Wu H.Y, Peng Y.S et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med 2017; 177: 792-9.

10. Yusuf S, Hawken S, Ounpuu S et al.; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.

11. Banegas J.R, Lopez-Garcia E, Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32: 2143-52.

12. Chow C.K, Teo K.K, Rangarajan S et al; PURE Study Investigators. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959-68.

13. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet 2014; 383: 1912-9.

14. Tocci G, Rosei E.A, Ambrosioni E et al. Blood pressure control in Italy: analysis of clinical data from 2005-2011 surveys on hypertension. J Hypertens 2012; 30: 1065-74.

15. Finucane M.M et al. National, regional, and global trends in body mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet Lond Engl 2011; 377 (9765): 557-67.

16. Caleyachetty R et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol 2017; 70 (12): 1429-37.

17. Guh D.P, Zhang W, Bansback N et al. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health 2009; 9 (88).

18. Anari R, Amani R, Latifi S.M et al. Association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects. Diabetes Metab Syndr Clin Res. Rev 2017; 11 (1): 37-41.

19. Wilson P.W.F, D’Agostino R.B, Sullivan L et al. Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience. Arch Intern Med 2002; 162 (16): 1867-72.

20. Mancusi C et al. Differential effect of obesity on prevalence of cardiac and carotid target organ damage in hypertension (the Campania Salute Network). Int J Cardiol 2017; 244: 260-4.

21. Ohnishi H et al. Incidence of Hypertension in Individuals with Abdominal Obesity in a Rural Japanese Population: The Tanno and Sobetsu Study. Hypertens Res 2008; 31 (7): 1385-90.

22. Jahangir E, Schutter ADe, Lavie C.J. The relationship between obesity and coronary artery disease. Transl Res 2014; 164 (4): 336-44.

23. Despres J.P, Moorjani S, Lupien P.J et al. Regional distribution of body fat, plasma insulin, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990; 10: 497-511.

24. Fox C.S, Massaro J.M, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007; 116: 39-48.

25. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-13.

26. Tatti P, Pahor M, Byington R.P et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.

27. Estacio R.O, Jeffers B.W, Hiatt W.R et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52.

28. Niskanen L, Hedner T, Hansson L et al. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091-6.

29. Lindholm L.H, Hansson L, Ekbom T et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000; 18: 1671-5.

30. Thomopoulosa C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertension 2017, 35: 922-44.

31. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. Head-to-head comparisons of various classes of antihypertensive drugs. Overview and meta-analyses. J Hypertens 2015; 33: 1321-41.

32. Elliott W.J, Meyer P.M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369 (9557): 201-7.

33. Edarbi® (azilsartan medoxomil) prescribing information. Takeda Pharmaceuticals America, Inc., 2012. Data on file. Takeda Pharmaceutical Company Limited.

34. Bönner G et al. Comparison of antihypertensive efficacy of the new angiotensin receptor blocker azilsartan medoxomil with ramipril. J Hypertens 2010; 28: e283.

35. White W.B et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-20.

36. Kusumoto K et al. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacology 2011; 669: 84-93.

37. Iwai M. TAK-536, a new receptor blocker, improved glucose intolerans and adipocyt differentiation. AJH 2007; 20: 579-86.

38. Недогода С.В., Чумачек Е.В., Цома В.В. и др. Возможности азилсартана в коррекции инсулинорезистентности и уровня адипокинов при артериальной гипертензии в сравнении с другими сартанами. Рос. кардиол. журн. 2019; 24 (1): 1-9. @@Nedogoda S.V., Chumachek E.V., Tsoma V.V. et al. Vozmozhnosti azilsartana v korrektsii insulinorezistentnosti i urovnia adipokinov pri arterial'noi gipertenzii v sravnenii s drugimi sartanami. Ros. kardiol. zhurn. 2019; 24 (1): 1-9. (in Russian).]

39. Чазова И.Е., Жернакова Ю.В., Блинова Н.В., Рогоза А.Н. Новый блокатор рецепторов к ангиотензину II Эдарби®, как часть патогенетического лечения артериальной гипертонии у больных с метаболическими нарушениями. Системные гипертензии. 2017; 14 (3): 28-35. DOI: 10.26442/2075-082X_14.3.28-35 @@Chazova I.E., Zhernakova Yu.V., Blinova N.V., Rogoza A.N. Novyi blokator retseptorov k angiotenzinu II Edarbi®, kak chast' patogeneticheskogo lecheniia arterial'noi gipertonii u bol'nykh s metabolicheskimi narusheniiami. Systemic Hypertension. 2017; 14 (3): 28-35. DOI: 10.26442/2075-082X_14.3.28-35 (in Russian).]

40. Williams B, Mancia G, Spiering W et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021-104.

41. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019; 16 (1): 6-31. @@Chazova I.E., Zhernakova Yu.V. ot imeni ekspertov. Klinicheskie rekomendatsii. Diagnostika i lechenie arterial'noi gipertonii. Systemic Hypertension. 2019; 16 (1): 6-31. DOI: 10.26442/2075082X.2019.1.190179 (in Russian).]

42. Gradman A.H, Parisé H, Lefebvre P et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension 2013; 61: 309-18.

43. Arnett D.K, Blumenthal R.S, Albert M.A et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019. DOI: 10.1161/CIR.0000000000000678

44. ALLHAT Officers and Coordinators; ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97.

45. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990; 82 (5): 1616-28.

46. Кurtz T.W. Chlorthalidone: don’t call it “thiazide-like” anymore. Hypertension 2010; 56: 335-7.

47. Carter B.L, Ernst M.E, Cohen J.D. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004; 43: 4-9.

48. George L. Bakris, M.D, Domenic Sica et al. Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. Am J Med 2012; 125 (12): 1229.e1-1229.e10

49. Cushman W.C, Bakris G.L et al. Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. Hypertension 2012; 60: 310-8.